Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Patients with Lipodystrophy Syndromes
Biomolecules · 2024
DOI: 10.3390/biom14111474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Michelle Krienke und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Liebigstraße 20, 04103 Leipzig, Germany. Hauptthemen laut MEDLINE: Lipodystrophy, Glycoproteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Diabetes Gesellschaft, Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) through CRC1052 “Obesity Mechanisms”.
Abstract (Originalsprache)
Serum concentrations of leucine-rich alpha-2 glycoprotein 1 (LRG1) are elevated in several cardio-metabolic and inflammatory diseases. LRG1 also plays an important role in the development of hepatic steatosis and insulin resistance. In lipodystrophies (LDs), severe cardio-metabolic complications can be observed. The dysregulation of several adipokines plays a significant role in the clinical manifestation of this syndrome. To date, there have been no studies of LRG1 levels in non-HIV-LD patients. We performed a cross-sectional analysis of LRG1 serum levels in 60 patients with non-HIV-associated LD and in 60 age-, sex-, and BMI-matched healthy controls. Furthermore, we investigated the gene expression of Lrg1 in a mouse model of generalised LD. No significant difference was found in the median concentration of LRG1 serum levels between LD patients (18.2 ng/L; interquartile range 8.3 ng/L) and healthy controls (17.8 ng/L; interquartile range 11.0 ng/L). LRG1 serum concentrations correlated positively with CRP serum levels (p < 0.001). Lrg1 mRNA expression was downregulated in the adipose tissue, whereas in the liver, no difference in Lrg1 expression between LD and wild-type mice was detected. In summary, circulating levels of LRG1 are associated with low-grade inflammation but cannot distinguish between patients with LD and controls.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Liebigstraße 20, 04103 Leipzig, Germany.
ORCID-Profile: Leonie Wagner
Förderung
- Deutsche Forschungsgemeinschaft
- Deutsche Diabetes Gesellschaft
- Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) through CRC1052 “Obesity Mechanisms”
- German Diabetes Association (DDG)
Zitieren
APA
Krienke, M., Kralisch, S., Wagner, L., Tönjes, A., & Miehle, K. (2024). Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Patients with Lipodystrophy Syndromes. Biomolecules. https://doi.org/10.3390/biom14111474
Vancouver
Krienke M, Kralisch S, Wagner L, Tönjes A, Miehle K. Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Patients with Lipodystrophy Syndromes. Biomolecules. 2024. doi:10.3390/biom14111474
BibTeX
@article{Krienke2024,
author = {Krienke, Michelle and Kralisch, Susan and Wagner, Leonie and Tönjes, Anke and Miehle, Konstanze},
title = {Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Patients with Lipodystrophy Syndromes},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14111474}
}
EUVIMED